MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Second Sight, Pixium Vision merger plans are over

Second Sight, Pixium Vision merger plans are over

By

pixium second sightSecond Sight Medical notified Pixium that it decided to unilaterally terminate a memorandum of understanding (MOU) ahead of a planned merger.

In a news release, Pixium said the $27.9 million private placement recently announced and closed by Second Sight was “not only explicitly prohibited under the terms of the [MOU] entered into by the companies on Jan. 5, 2021, but also detrimental to Pixum Vision’s interests.”

Paris-based Pixium said it offered to Second Sight a chance to renegotiate the MOU in order to continue pursuing the business combination while preserving contractual balance and the interests of the company and its shareholders, but the company said Second Sight never responded to the proposals, nor did it demonstrate any willingness to reach such an agreement.

Following the refusal to enter renegotiation discussions, Second Sight notified Pixium on Friday that it decided to terminate the MOU, notwithstanding that the MOU does not provide the company with this right, according to Pixium.

Pixium said it acknowledges the “wrongful termination” of the MOU and the planned merger by Second Sight and is considering all measures available, including potential legal proceedings, to preserve its rights and receive compensation for any damages.

“While we are naturally disappointed in the position being taken by Second Sight and that this business combination has not proceeded, Pixium Vision is in a strong position both financially and clinically, with a world-class research & development team and core expertise in vision neuromodulation and a solid patent portfolio,” Pixium CEO Lloyd Diamond said in the release. “We are continuing our transition from a research organization to a commercially oriented company with the recent initiation of our PRIMAvera pivotal trial of the Prima System. Our ambition is to be the first company in the world to bring a retinal implant solution to the millions of people worldwide suffering with Dry-AMD and expand this to other retinal diseases.

“This is supported by the newly reported data showing patients could simultaneously use prosthetic central vision generated with the Prima System and their remaining peripheral vision. We are well positioned to continue the development of this exciting bionic vision system and bring it to market to improve patients’ quality of life.”

In case you missed it

RSS From Medical Design & Outsourcing

  • Steris plans to build a new medical device testing facility
    Steris (NYSE: STE) plans to build a new packaging and microbiological testing facility for medical devices in Leipzig, Germany. The facility will offer packaging testing services such as accelerated and real-time aging, transportation and integrity testing. The new location will also offer microbiological testing in collaboration with the medical device manufacturer and sterilizer’s laboratory in… […]
  • 10 medical device startups you need to know
    Some of the most interesting medical device startups of 2022 are advancing a wide range of innovative medtech: robotics, catheter-delivered brain-computer interfaces and more. The editors here at Medical Design & Outsourcing and MassDevice are writing about medical device startups all the time. But there are some device companies starting out that have technologies that… […]
  • Steris stock downgraded as analysts expect lawyers to seek more ethylene oxide lawsuits
    Steris (NYSE: STE) stock was downgraded today by Needham from buy to hold following the $363 million jury verdict against its primary competitor, Sterigenics, over ethylene oxide (EtO) emissions. Needham analysts said they expect attorneys to target communities near EtO facilities with ads to find people willing to file more lawsuits against sterilization plant operators… […]
  • Researchers develop at-home device to track Parkinson’s progression
    Researchers at MIT and the University of Rochester Medical Center have developed a device to monitor a Parkinson’s patient at home. Collecting data at home could help provide a less subjective measurement than evaluations at the doctor’s office, which can be affected by outside factors. The technology could also help pharmaceutical and biotech companies developing… […]
  • Micro Mold renovates for new 5-axis milling center
    Precision mold maker Micro Mold has renovated in Erie, Pennsylvania, to make room for its new Yasda YMC650 high-speed 5-axis milling center and 3R Workpartner automation cell. The new equipment will be used for electrode manufacturing and finishing hard mill applications. The milling machine is accurate to 1 micron for high-volume, ultra-precision tooling work, the… […]
  • September 2022 Issue: The Medtech Big 100 is bigger than ever
    Medtech sales reach a record high as R&D spend and employee counts climb Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future Autotransfusion device maker ships units to Ukraine How IP protection is enabling robotic surgery innovation Connected device design for the real world: Managing the development process FDA details plans to expand… […]
  • How NeuroOne and Zimmer Biomet will partner on robotic brain surgery
    NeuroOne (NASDAQ: NMTC) is preparing its depth electrode technology for commercialization through Zimmer Biomet (NYSE: ZBH) while waiting for FDA feedback on its latest submission. NeuroOne’s Evo stereoelectroencephalography (sEEG) device won FDA 510(k) clearance in September 2021 for recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain. That clearance was… […]
  • Trelleborg to show off advanced polymer tech at MD&M Minneapolis
    Trelleborg Healthcare & Medical will exhibit advanced polymer technologies for medical applications at MD&M Minneapolis, which runs Nov. 2–3, 2022. The Sweden-based engineering polymer giant, which has operations in 50 companies, has newly acquired, advanced capabilities in thermoplastic injection molding. The new injection molding capabilities come from its purchase of Menomonie, Wisconsin–based EirMed earlier this… […]
  • Millstone Medical Outsourcing expands cleanroom facility
    Millstone Medical Outsourcing said today that it has broken ground on a 5,000-square-foot cleanroom facility expansion at its Fall River, Massachusetts headquarters. The project is Millstone’s third cleanroom expansion. The additional Class 10,000/ISO7-rated cleanroom space is for medical device packaging operations. It will bring the company’s total cleanroom footprint to 20,000 square feet. Responding to… […]
  • Johnson & Johnson launches Bay Area science and technology campus
    Johnson & Johnson (NYSE:JNJ) has opened an almost 200,000 ft2 science and technology campus in the San Francisco Bay Area. The new facility more than doubles the presence of the company in the Bay Area, which has been a hub for life sciences innovation for decades. Up to 400 employees will work at the facility. “This… […]
  • VitalPath opens new Design Center in Minnesota
    VitalPath announced today that it recently opened a new Design Center in the Minneapolis suburb of New Hope. The Minnesota-based company manufactures custom, highly complex catheter solutions for major medical device companies. It says the new Design Center brings its entire design and prototyping capabilities under one roof in order to accelerate time to market.… […]